Rocío is a medical doctor with a PhD in human genetics and a decade of experience analyzing genetic data and studying variants. She completed her PhD at Radboud University Nijmegen and was a postdoctoral fellow at the Max-Planck Institute for Molecular Genetics in Berlin. She has numerous publications in prestigious journals and received the Young Investigator Award for Outstanding Science from the European Society for Human Genetics for her doctoral research (2016).

Johan den Dunnen studied biology at the Catholic University Nijmegen (Nederland). In the same university he received his PhD in Molecular Biology for his work on the "Evolution of eye-lens crystallin genes". After his PhD he moved to the department of Human Genetics (Leiden University) and became involved in the search for the gene causing Duchenne/Becker muscular dystrophy. He is currently employed at the Center for Human and Clinical Genetics (Leiden University Medical Center, Leiden, Nederland), studying genetic disease in general and neuromuscular disorders (DMD/BMD, LGMD) in particular. As professor in "Medical Genomics" he focuses on the use of new high-throughput technology in research and diagnosis of genetic disease, in particular the development of methods to detect DNA variants and the application of next generation sequencing. To spread the laboratories knowledge on hereditary muscle disease he initiated the "Leiden Muscular Dystrophy pages" (http://www.DMD.nl). As part of these efforts he currently curates over 50 gene sequence variant databases. His group developed the freely available LSDB-in-a-Box software package LOVD, the Mutalyzer tool (HGVS sequence variant description) and he participates in the EU FP7 Gen2Phen project (WP leader for gene variant databases [LSDBs]). 

TO BE CONFIRMED. Ivo Gut took on the direction of CNAG in January 2010.

He qualified in Chemistry at the University of Basel in 1985 and obtained a PhD in Physical Chemistry from the same university in 1990. Then he joined the research group of Prof. Irene Kochevar at Harvard Medical School as a research fellow.

Between 1993 and 1996 he was research fellow with Dr. Stephan Beck at the Imperial Cancer Research Fund in London. Later, at the Max-Planck-Institute for Molecular Genetics he led a group in the Department for Vertebrate Genomics of Prof. Hans Lehrach.

In the 11 years before joining the CNAG he worked at the Centre National de Génotypage of the Commissariat à l'Energie Atomique in Evry, France, first as Head of Technology Development and later as Associate Director under Prof. Mark Lathrop.

His research interests are high-throughput nucleic acid analysis, sequencing, SNP genotyping, genomics, genetics, nucleic acid and protein analysis methods (molecular biological techniques and chemical modification), implementation of methods, automation and analysis.

He is the author of over 100 research papers, inventor of 24 patents and patent applications, founder of 4 biotech companies (Genom Analytik GmbH, Biopsytec GmbH and Epigenomics AG, Integragen SA). He is the coordinator of the 12M€ EU FP7-funded Integrated Project READNA on DNA sequencing technology development.

Reece Hart is a Research and Engineering Fellow at Invitae, a clinical genome diagnostics company, where he is part of the team building reliable systems to analyze, interpret, and communicate sequence variation. He is an active member of the Global Alliance for Genomics and Health, an international, non-profit alliance that is building a common framework of technical and ethical standards to enable the responsible, voluntary, and secure sharing of genomic and clinical data. He was previously director of engineering at 23andMe, the Chief Scientist for UC Berkeley's Genome Commons, and a scientist in target discovery and manager of research computing at Genentech. He received his PhD in molecular biophysics and Masters in computer science from Washington University in St. Louis.

Alexander Hoischen is affiliated with the department of Human Genetics and the department of Internal Medicine of the Radboudumc, and operates within the Radboudumc research theme Infectious diseases and global health. He and his research group are fascinated by the application of latest genomics technologies to understand the genetic basis of rare (immune) disorders. He is also the Scientific Director of the Radboud Technology Center Genomics.

Technological advances summarized as next generation sequencing (NGS) have changed human genetics dramatically in the last 15 years. For the first time we can read the genome, or the coding portion of the genome a.k.a. the exome, of many individuals; and this has changed the research and diagnostics of human diseases, in particular rare diseases. In addition, novel NGS-based approaches allow to read DNA with much improved accuracy allowing somatic mutation detection in an unprecedented way.

Our group has been involved in several discoveries of novel rare disease genes, with a recent focus on rare immunological diseases. We however face the challenge that in a large proportion of patients (30-80% depending on disease) with a likely rare genetic disease remains unexplained even after exome sequencing. Within the group ‘genomic technologies and immuno-genomics’, we aim to establish novel –omics methods and integrate the novel –omics data with existing data to boost the discovery of genetic causes of (rare (immunological)) diseases.

Within our group and together with our collaborators we envision novel themes that all go ‘beyond the exome’ and will ultimately improve (rare) disease genetics in research and diagnostics. Specific focus will be on: 1. Better analyses of existing exomes and move to genomes, 2. long-read genomes, 3. integration of the effect of rare and common variants, 4. integration of transcriptomics and genomics (and other –omics), 5. more accurate sequencing for somatic mutation detection, 6. early adoption of latest technologies for the benefit of immunology, pathology, and genetics.

Andreas Laner, PhD

Head of Genomics Program

Areas of Specialization

• Genetics of hereditary cancer syndromes
• Next-generation sequencing applications
• Interpretation and classification of sequence variants

Education & Experience

• Diploma in Biology, Ludwig Maximilian University, Munich
• PhD, Ludwig Maximilian University, Munich

Professional affiliations

• MGZ Munich, Head of Genomics Applications
• Member, European Society of Human Genetics
• Curator, Leiden Open Variation Database
• Organizational Committee, Variant Effect Prediction Training Course, Crete 2016
• Scientific Program Committee, 14th International Symposium on Variants in the Genome, Santiago de Compostela 2017